Association of 25-hydro xyvitamin D and ferritin with metabolic associated fatty liver disease and fibrosis-4 index

Wenhao LI; Zhiping LIU; Zhiwei ZHAO; Jinhua ZHANG

doi:10.3969/j.issn.1001-5256.2023.08.015

Volume 39 Issue 8

Aug. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(8): 1867-1873

PDF( 2200 KB)

Association of 25-hydro xyvitamin D and ferritin with metabolic associated fatty liver disease and fibrosis-4 index

DOI: 10.3969/j.issn.1001-5256.2023.08.015

Department of Gastroenterology, Wuhan Hankou Hospital, Wuhan 430012, China

Research funding:

Key Project of Wuhan Municipal Health Commission (WX20A08)

More Information

Corresponding author: LIU Zhiping, xiao6599@sina.com (ORCID: 0000-0002-3447-0356)
Received Date: 2022-11-12
Accepted Date: 2022-12-12
Published Date: 2023-08-20

Abstract

Abstract

Objective To investigate the association of serum 25-hydroxyvitamin D [25(OH)D] and serum ferritin (SF) with metabolic associated fatty liver disease (MAFLD) and fibrosis-4 (FIB-4) index. Methods A retrospective analysis was performed for the clinical data of 595 patients who were hospitalized in Department of Gastroenterology, Wuhan Hankou Hospital, from August 2020 to December 2021. Clinical features were compared between 242 patients with MAFLD and 353 patients without MAFLD, and the prevalence rate of MAFLD and SF level were compared between the groups with different 25(OH)D levels. The non-normally distributed continuous data were expressed as M(P₂₅-P₇₅), and the Mann-Whitney U test was used for comparison between two groups; the chi-square test was used for comparison of categorical data between groups. A Spearman correlation analysis was used to investigate the correlation between serum 25(OH)D and SF in different populations; a binary logistic regression analysis was used to investigate the association of 25(OH)D and SF with the risk of MAFLD and FIB-4 index; the receiver operating characteristic (ROC) curves were used to assess the value of 25(OH)D and SF in the diagnosis of liver fibrosis in patients with MAFLD. Results Compared with the non-MAFLD patients, the MAFLD patients had a significant reduction in serum 25(OH)D level [15.35(11.26-20.02) vs 21.71(15.39-27.84), Z=-9.761, P < 0.05] and a significant increase in SF level [365.50(251.75-525.00) vs 205.00(112.50-275.00), Z=-13.317, P < 0.05]. The prevalence rate of MAFLD and SF level tended to increase with the reduction in serum 25(OH)D level (Z=75.512, P < 0.05). Serum 25(OH)D level was significantly negatively correlated with SF in MAFLD patients (r=-0.460, P < 0.05). The logistic regression analysis showed that the reduction in serum 25(OH)D level (odds ratio [OR]=0.934, 95% confidence interval [CI]: 0.879-0.992, P=0.028) and the increase in SF level (OR=1.009, 95%CI: 1.006-1.013, P < 0.001) were independent risk factors for MAFLD, and the reduction in serum 25(OH)D level (OR=0.852, 95%CI: 0.752-0.965, P=0.012) was also an independent risk factor for elevated FIB-4 index (> 2.67) in MAFLD patients. The ROC curve analysis showed that serum 25(OH)D, SF, and their combination had an area under the ROC curve of 0.793, 0.829, and 0.851, respectively, in predicting elevated FIB-4 index (> 2.67) in MAFLD patients (all P < 0.05). Conclusion Serum 25(OH)D is negatively correlated with SF, and the reduction in serum 25(OH)D and the increase in SF are associated with the risk of MAFLD and elevated FIB-4 index. Serum 25(OH)D and SF levels have a certain value in predicting liver fibrosis in patients with MAFLD.
- Metabolic-Associated Fatty Liver Disease,
- 25-Hydroxyvitamin D,
- Ferritin,
- Hepatic Fibrosis

FullText(HTML)

References(20)

References

[1]	LAZARUS JV, MARK HE, ANSTEE QM, et al. Advancing the global public health agenda for NAFLD: A consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(1): 60-78. DOI: 10.1038/s41575-021-00523-4.
[2]	DU SX, LU LL, GENG N, et al. Association of serum ferritin with non-alcoholic fatty liver disease: A meta-analysis[J]. Lipids Health Dis, 2017, 16(1): 228. DOI: 10.1186/s12944-017-0613-4.
[3]	ALI SANGOUNI A, GHAVAMZADEH S, JAMALZEHI A. A narrative review on effects of vitamin D on main risk factors and severity of non-alcoholic fatty liver disease[J]. Diabetes MetabSyndr, 2019, 13(3): 2260-2265. DOI: 10.1016/j.dsx.2019.05.013.
[4]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[5]	LIN S, HUANG JF, WANG MF, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40(9): 2082-2089. DOI: 10.1111/liv.14548.
[6]	CIARDULLO S, PERSEGHIN G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population[J]. Liver Int, 2021, 41(6): 1290-1293. DOI: 10.1111/liv.14828.
[7]	SHAH AG, LYDECKER A, MURRAY K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2009, 7(10): 1104-1112. DOI: 10.1016/j.cgh.2009.05.033.
[8]	LIAO XP, ZHANG ZL, ZHANG HH, et al. Application guideline for vitamin D and bone health in adult Chinese(2014 standard edition) vitamin D working group of osteoporosis committee of China gerontological society[J]. Chin J Osteoporos, 2014, 20(9): 1011-1030. DOI: 10.3969/j.issn.1006-7108.2014.09.002. 廖祥鹏, 张增利, 张红红, 等. 维生素D与成年人骨骼健康应用指南(2014年标准版)[J]. 中国骨质疏松杂志, 2014, 20(9): 1011-1030. DOI: 10.3969/j.issn.1006-7108.2014.09.002.
[9]	ZHOU Q, LI JQ, LI XW. Influence of vitamin D deficiency on fibrosis-4 index and disease severity in patients with nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2022, 38(6): 1293-1298. DOI: 10.3969/j.issn.1001-5256.2022.06.015. 周荃, 李金强, 黎晓武. 维生素D缺乏对非酒精性脂肪性肝炎患者FIB-4指数及病情严重程度的影响[J]. 临床肝胆病杂志, 2022, 38(6): 1293-1298. DOI: 10.3969/j.issn.1001-5256.2022.06.015.
[10]	SUN CJ, ZUO XQ, YAO N, et al. Study on the correlation between serum ferritin and non-alcoholic fatty liver disease[J]. Zhejiang J Integr Tradit Chin West Med, 2019, 29(5): 371-375. DOI: 10.3969/j.issn.1005-4561.2019.05.008. 孙彩娟, 左昔清, 姚娜, 等. 血清铁蛋白与非酒精性脂肪性肝病相关性研究[J]. 浙江中西医结合杂志, 2019, 29(5): 371-375. DOI: 10.3969/j.issn.1005-4561.2019.05.008.
[11]	BACCHETTA J, ZARITSKY JJ, SEA JL, et al. Suppression of iron-regulatory hepcidin by vitamin D[J]. J Am Soc Nephrol, 2014, 25(3): 564-572. DOI: 10.1681/ASN.2013040355.
[12]	LIU ZP, ZHANG JH, WANG XN, et al. Effect of vitamin D on serum markers of iron metabolism in patients with non-alcoholic fatty liver disease[J]. Tianjin Med J, 2018, 46(12): 1316-1318. DOI: 10.11958/20180847. 刘志平, 张金华, 王湘宁, 等. 维生素D对非酒精性脂肪性肝病患者铁代谢的影响[J]. 天津医药, 2018, 46(12): 1316-1318. DOI: 10.11958/20180847.
[13]	PATEL YA, GIFFORD EJ, GLASS LM, et al. Identifying nonalcoholic fatty liver disease advanced fibrosis in the veterans health administration[J]. Dig Dis Sci, 2018, 63(9): 2259-2266. DOI: 10.1007/s10620-018-5123-3.
[14]	MA XH, ZHANG X, YOU Y, et al. Diagnostic value of APRI combined with FIB-4 for significant liver fibrosis in patients with chronic hepatitis B[J]. Chin J Gastroenterol, 2017, 22(9): 544-547. DOI: 10.3969/j.issn.1008-7125.2017.09.007. 马晓辉, 张新, 游云, 等. APRI、FIB-4联合对慢性乙型肝炎患者显著肝纤维化的诊断价值[J]. 胃肠病学, 2017, 22(9): 544-547. DOI: 10.3969/j.issn.1008-7125.2017.09.007.
[15]	YANG BB, CHEN YH, ZHANG C, et al. Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Endocrine, 2017, 55(2): 582-590. DOI: 10.1007/s12020-016-1152-x.
[16]	UDOMSINPRASERT W, JITTIKOON J. Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies[J]. Biomed Pharmacother, 2019, 109: 1351-1360. DOI: 10.1016/j.biopha.2018.10.140.
[17]	KOWDLEY KV, BELT P, WILSON LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2012, 55(1): 77-85. DOI: 10.1002/hep.24706.
[18]	BUZZETTI E, PETTA S, MANUGUERRA R, et al. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease[J]. Liver Int, 2019, 39(7): 1325-1334. DOI: 10.1111/liv.14096.
[19]	YONEDA M, THOMAS E, SUMIDA Y, et al. Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution[J]. Hepatol Res, 2014, 44(14): E499-E502. DOI: 10.1111/hepr.12327.
[20]	ZENG J, FAN JG. Clinical significance of renaming nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002. 曾静, 范建高. 非酒精性脂肪性肝病更名的临床意义[J]. 临床肝胆病杂志, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.

Relative Articles

[1]	Yingdie ZHU, Zhijiao ZHANG, Guilin ZHANG, Yunkun GAO, Mengyao ZHENG, Hua HUANG, Gongfang ZHAO. Association of metabolic associated fatty liver disease with carotid atherosclerotic plaque and stenosis[J]. Journal of Clinical Hepatology, 2024, 40(8): 1591-1597. doi: 10.12449/JCH240814
[2]	Linlin WU, Fan ZHANG. Expression of serum 25-hydroxyvitamin D and its clinical significance in patients with nonalcoholic fatty liver disease and obesity[J]. Journal of Clinical Hepatology, 2024, 40(7): 1349-1353. doi: 10.12449/JCH240711
[3]	Xiaodong ZHOU, Na TIAN, Minghua ZHENG. Excerpt of an international multidisciplinary consensus statement on MAFLD and the risk of CVD （2023）[J]. Journal of Clinical Hepatology, 2023, 39(10): 2336-2339. doi: 10.3969/j.issn.1001-5256.2023.10.010
[4]	Shuang ZHANG, Xiaohui LIU, Gang WANG, Li ZHANG, Yunjie ZHU, Jian WU, Yali LIU, Jing ZHANG. Population differences of metabolic associated fatty liver disease and nonalcoholic fatty liver disease based on a community elderly population[J]. Journal of Clinical Hepatology, 2022, 38(3): 547-552. doi: 10.3969/j.issn.1001-5256.2022.03.011
[5]	Yunxia WU, Chengliang LI, Xiaolei LI, Zhaoxiao LUO, Tianshun REN. Correlation between cardiometabolic index and metabolic-associated fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(10): 2247-2251. doi: 10.3969/j.issn.1001-5256.2022.10.010
[6]	Ling LUO, Xianhua LIAO, Bihui ZHONG. Research advances in vitamin D deficiency and metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(7): 1641-1645. doi: 10.3969/j.issn.1001-5256.2022.07.034
[7]	Lidan YANG, He HE, Zhenmei AN. Role of intestinal flora in metabolic-associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2231-2235. doi: 10.3969/j.issn.1001-5256.2021.09.046
[8]	Qianqian XIAO, Mengyu WANG, Jiangao FAN. Brief introduction of APASL clinical practice guidelines on metabolic associated fatty liver disease (Treatment Part)[J]. Journal of Clinical Hepatology, 2021, 37(1): 41-45. doi: 10.3969/j.issn.1001-5256.2021.01.009
[9]	Junzhao YE, Yansong LIN, Bihui ZHONG. Research advances in dietary intervention in the treatment of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(3): 709-713. doi: 10.3969/j.issn.1001-5256.2021.03.042
[10]	Lei MIAO, Liangjie TANG, Jiangao FAN, Minghua ZHENG. Acute-on-chronic liver failure in patients with metabolic associated fatty liver disease: Past, Present, and Future[J]. Journal of Clinical Hepatology, 2021, 37(4): 761-764. doi: 10.3969/j.issn.1001-5256.2021.04.004
[11]	Sutong LIU, Kaiqi SU, Chenlu ZHAO, Lihui ZHANG, Wenxia ZHAO. Research advances in medical treatment of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 947-950. doi: 10.3969/j.issn.1001-5256.2021.04.048
[12]	Jiahui LYU, Xiaofei LI, Lianyi GUO. Association between metabolic associated fatty liver disease and sleep disorders[J]. Journal of Clinical Hepatology, 2021, 37(12): 2854-2860. doi: 10.3969/j.issn.1001-5256.2021.12.024
[13]	Xue Rui, Fan JianGao. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1224-1227. doi: 10.3969/j.issn.1001-5256.2020.06.007
[14]	Wen Jun, Li Jia, Wang ChunYan, Ma Ying. Value of serum PIVKA-Ⅱ, alpha-fetoprotein, and ferritin in assisting the diagnosis of HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(9): 1729-1733. doi: 10.3969/j.issn.1001-5256.2017.09.020
[15]	You ChunFang, Zhou LiMin, Deng Wei. Correlation between serum ferritin level and antiviral effect of pegylated interferon in chronic hepatitis C patients with genotype 1b[J]. Journal of Clinical Hepatology, 2017, 33(9): 1713-1716. doi: 10.3969/j.issn.1001-5256.2017.09.016
[16]	Ou Qiang, Wang Yang, Xu YanHua, Ning HuiMing, Huang Ling, Tang Qun. Changes in serum markers of iron metabolism and their clinical significance in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(12): 2360-2363. doi: 10.3969/j.issn.1001-5256.2016.12.026
[17]	Zhao Bin, Ma ZhenQi. Serum levels of adiponectin and ferritin and their clinical significance in patients with nonalcoholic fatty liver in Qinghai,China[J]. Journal of Clinical Hepatology, 2016, 32(10): 1955-1958. doi: 10.3969/j.issn.1001-5256.2016.10.028
[18]	Cai Wen, Dong ZhengHui, Wang ShuXia, Yang XiaoPing, Yao Hua. Analysis of correlation between serum 25- hydroxyvitamin D level and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1059-1062. doi: 10.3969/j.issn.1001-5256.2015.07.015
[19]	Yang WeiMin, Xin GuiJie, Ding ShengNan. Levels and clinical significance of serum 25-hydroxy vitamin D in patients with chronic liver disease[J]. Journal of Clinical Hepatology, 2015, 31(5): 754-757. doi: 10.3969/j.issn.1001-5256.2015.05.029
[20]	Jin HongHui, Li ZhongPing. Correlational research of serum ferritin and hyaluronic acid in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(3): 216-218.

Supplements(0)

Cited By

Cited by

Periodical cited type(1)

叶丝陶，艾英杰，李星寰，房晔，姜思雨，黄晓铨，陈世耀. 乙肝肝硬化伴食管胃静脉曲张患者合并门静脉血栓的铁代谢特征改变. 中国医师杂志. 2024(04): 489-493 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (476) PDF downloads(54)

Association of 25-hydro xyvitamin D and ferritin with metabolic associated fatty liver disease and fibrosis-4 index

DOI: 10.3969/j.issn.1001-5256.2023.08.015